Impact of acoramidis on clinical stability in transthyretin amyloid cardiomyopathy: Observations from ATTRibute-CM - PubMed
4 hours ago
- #acoramidis
- #clinical improvement
- #ATTR-CM
- Acoramidis is an oral transthyretin (TTR) stabilizer achieving near-complete TTR stabilization.
- Post-hoc analysis of ATTRibute-CM trial evaluated NT-proBNP and 6MWD changes in ATTR-CM patients.
- Clinically meaningful improvement (CMI) criteria: NT-proBNP decrease >700 ng/L and >30%, or 6MWD increase >35 m.
- 611 participants analyzed (409 acoramidis, 202 placebo). Baseline NT-proBNP and 6MWD were similar in both groups.
- Significantly higher CMI achieved with acoramidis (22.7%) vs. placebo (8.9%) (OR 3.0, 95% CI 1.8-5.1; p < 0.001).
- Acoramidis may shift ATTR-CM treatment from slowing progression to achieving improvement.